PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1989 May; 82(5): 272–275.
PMCID: PMC1292130

Safety and efficacy of nifedipine 20 mg tablets in hypertension using electronic data collection in general practice.

Abstract

Electronic data collection was used in this open study to survey the safety and efficacy of nifedipine when used in the treatment of 3972 patients with mild to moderate essential hypertension. The safety and efficacy results are presented and discussed as well as the advantages, disadvantages and reliability of electronic data collection. The validity of data collected electronically has not previously been tested, such data having been assumed to be reliable. The pattern of adverse events reported in this study is compared with the pattern of reports to the Committee on Safety of Medicine (CSM), to Bayer UK and in a large paper-based study of nifedipine, in order to test these assumptions. Reported adverse medical events pre-treatment, prior to entry to the study and noted at visit 1, were compared with reports during treatment in the study at visits 2 and 3. The expected incidence of flushing and headache was seen which diminished with continued treatment. Reductions were seen in dyspnoea and impotence. Ankle oedema was observed and was not reduced by time alone. After one month of treatment with nifedipine 20 mg tablets twice daily, 66.5% of patients had a sitting phase V diastolic blood pressure of 90 mmHg or below and 79% of 95 mmHg or below.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (737K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Chalmers D, Dombey SL, Lawson DH. Post marketing surveillance of captopril (for hypertension): a preliminary report. Br J Clin Pharmacol. 1987 Sep;24(3):343–349. [PMC free article] [PubMed]
  • Colin Jones DG, Langman MJ, Lawson DH, Vessey MP. Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report. Q J Med. 1985 Mar;54(215):253–268. [PubMed]
  • Barnett DB, Woods KL. Post-marketing surveillance or drug acceptability study? Br J Clin Pharmacol. 1987 Sep;24(3):281–282. [PMC free article] [PubMed]
  • Barnes PJ, Wilson NM, Brown MJ. A calcium antagonist, nifedipine, modifies exercise-induced asthma. Thorax. 1981 Oct;36(10):726–730. [PMC free article] [PubMed]
  • Duffy J, Macdonald G. The antihypertensive efficacy of nifedipine alone and in combination in general practice. Curr Med Res Opin. 1987;10(8):566–572. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press